Michael C Holmes

USPTO Granted Patents = 64 (Patent Applications = 16)

CIPO Patents = 25 (Patent Applications = 12)

EPO Patents = 28 (Patent Applications = 36)

Average Co-Inventor Count = 3.5

ph-index = 15

Forward Citations = 1,264(Granted Patents)

Forward Citations (Not Self Cited) = 1,142(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Oakland, CA (US) (2011 - 2021)
Richmond, CA (US) (2013 - 2023)
Brisbane, CA (US) (2024)

Company Filing History:

34 out of 160

Sangamo Biosciences, Inc.

patents

30 out of 145

Sangamo Therapeutics, Inc.

patents

7 out of 50

Ospedale San Raffaele S.r.l.

patents

4. 3 out of 5,445

University of Texas System

patents

5. 2 out of 15,462

University of California

patents

6. 2 out of 281

The Children's Hospital of Philadelphia

Sigma-aldvich Co. LLC

patent

9. 1 out of 1,628

University of Southern California

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

Areas of Expertise:

Gene Inactivation

Nuclease-Mediated Genome Engineering

T Cell Receptor Modification

Hematopoietic Stem Cells

PD1 Modulation

Targeted Integration

Zinc Finger Proteins

Genetic Condition Treatment

Hemophilia Therapy

CXCR4 Modification

Transgene Expression

Cystic Fibrosis Gene Alteration

64 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11884930 - Method of inactivating a glucocorticoid receptor gene in an isolated cell (2024-01-30),

2. 11793888 - Methods and compositions for engineering immunity (2023-10-24),

3. 11648267 - Methods and compositions for gene inactivation (2023-05-16),

4. 11591622 - Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder (2023-02-28),

5. 11492643 - Methods and compositions for treatment of a genetic condition (2022-11-08),

6. 11439666 - Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases (2022-09-13),

7. 11311574 - Methods and compositions for targeted cleavage and recombination (2022-04-26),

8. 11236175 - T cell modifying compounds and uses thereof (2022-02-01),

9. 11235026 - Methods and compositions for modulating PD1 (2022-02-01),

10. 10918668 - Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases (2021-02-16),

11. 10907175 - Isolated human cell with an inactivated glucocorticoid receptor gene (2021-02-02),

12. 10858416 - Methods and compositions for modification of a HLA locus (2020-12-08),

13. 10717993 - Methods and compositions for increased transgene expression (2020-07-21),

14. 10675302 - Methods and compositions for targeted cleavage and recombination (2020-06-09),

15. 10639383 - Methods and compositions for engineering immunity (2020-05-05),

Title: The Innovative Journey of Michael C Holmes

Introduction: Michael C Holmes, a talented inventor hailing from Richmond, CA, has made significant contributions to the world of technology and innovation.

Latest Patents: Michael C Holmes has recently been granted patents for cutting-edge inventions in the fields of renewable energy and sustainable materials.

Career Highlights: With a career spanning over two decades, Michael C Holmes has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing groundbreaking solutions. His work has been recognized globally for its impact and ingenuity.

Collaborations: Throughout his career, Michael C Holmes has collaborated with leading research institutions, universities, and innovative companies to bring his inventions to life. His ability to work across disciplines and industries has led to the creation of truly revolutionary products.

Conclusion: Michael C Holmes continues to push the boundaries of innovation, inspiring the next generation of inventors to think outside the box and create a better future for all.

This text is generated by artificial intelligence and may not be accurate.